SGHT
$8.28
+$0.53 (6.84%)+6.84%
ClosedLoading chart...
IndexN/A
Market Cap0.45B
Enterprise Value0.36B
Income$-0.01B
Sales$0.02B
EmployeesN/A
P/E-14.79
P/S5.35
P/B6.47
P/C-13.82
EV/EBITDA-11.05
EV/SalesN/A
EPS (ttm)-0.56
EarningsN/A
Gross Margin86.17%
Oper. Margin-47.95%
Profit Margin-49.67%
Volume0.49M
Shs Outstand0.05B
Change6.84%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | $79.87M | $81.06M | $71.33M | $48.96M | $27.64M | $23.35M | $7.53M |
| Cost of Revenue | $11.58M | $11.88M | $12.36M | $8.61M | $9.21M | $6.54M | $2.34M |
| Gross Profit | $68.28M | $69.17M | $58.97M | $40.35M | $18.43M | $16.80M | $5.19M |
| Gross Margin | 85.50% | 85.34% | 82.67% | 82.41% | 66.68% | 71.97% | 68.95% |
| Operating Expenses | $118.82M | $126.45M | $142.92M | $91.82M | $50.62M | $40.84M | $19.49M |
| Operating Income | $-50.53M | $-57.27M | $-83.95M | $-51.48M | $-32.19M | $-24.04M | $-14.30M |
| Operating Margin | -63.27% | -70.66% | -117.70% | -105.15% | -116.45% | -102.96% | -189.87% |
| Net Income | $-51.51M | $-55.55M | $-86.24M | $-62.96M | $-34.69M | $-25.87M | $-14.29M |
| Net Margin | -64.49% | -68.53% | -120.90% | -128.61% | -125.52% | -110.80% | -189.77% |
| EPS (Basic) | $-1.03 | $-1.14 | $-1.80 | $-1.33 | $-0.74 | $-0.55 | $-0.44 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $142.84M | $166.65M | $213.07M | $280.19M | $72.81M | $30.74M | $8.09M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $55.32M | $46.44M | $53.00M | $48.08M | $161.66M | $85.42M | $37.06M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $87.52M | $120.22M | $160.08M | $232.11M | $-88.85M | $-54.68M | $-28.96M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $87.52M | $120.22M | $160.08M | $232.11M | $-88.85M | $-54.68M | $-28.96M |
| Total Liabilities & Stockholders Equity | $142.84M | $166.65M | $213.07M | $280.19M | $72.81M | $30.74M | $8.09M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Net Income | $-51.51M | $-55.55M | $-86.24M | $-62.96M | $-34.69M | $-25.87M | $-14.29M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-22.35M | $-47.18M | $-75.97M | $-52.54M | $-32.17M | $-25.00M | $-14.47M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
UnitedHealthcare Adds Sight Sciences OMNI System To Covered Glaucoma Surgery ProceduresBenzinga Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye DiseaseGlobeNewswire Inc. Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye DiseaseGlobeNewswire Inc. Dry Eye Treatment Devices Market Poised to Attain Valuation of US$ 898.78 Million By 2033 | Pharmacological Synergy Driving Demand for Advanced Dry Eye Treatment Devices Says Astute AnalyticaGlobeNewswire Inc. Sight Sciences to Report Second Quarter Financial Results on August 1, 2024 - GlobeNewswireGlobeNewswire Inc. Sight Sciences CFO Alison Bauerlein sells over $65k in company stock By Investing.com - Investing.comInvesting.com Sight Sciences Announces the Release of its First Sustainability ReportGlobeNewswire Inc. Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from RestasisGlobeNewswire Inc.
Show 12 more stories
Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced GlaucomaGlobeNewswire Inc. Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma SurgeryGlobeNewswire Inc. Sight Sciences to Report First Quarter Financial Results on May 2, 2024GlobeNewswire Inc. Sight Sciences gibt die Veröffentlichung einer groß angelegten, praxisnahen MIGS-Studie als Nachweis für die Wirksamkeit des umfassenden Verfahrens zur Wiederherstellung des Kammerwasserabflusses mit der OMNI® Surgical System-Technologie sowohl bei der Senkung des Augeninnendrucks als auch bei der Einnahme von Medikamenten zur Senkung des Augeninnendrucks über einen Zeitraum von 2 Jahren bei Patienten mit Glaukom bekanntGlobeNewswire Inc. Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with GlaucomaGlobeNewswire Inc. Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual MeetingGlobeNewswire Inc. Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare ConferenceGlobeNewswire Inc. Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024GlobeNewswire Inc. Sight Sciences (SGHT) to Expand in Europe With New LaunchZacks Investment Research Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter MeetingGlobeNewswire Inc.
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate intraocular pressure in adult glaucoma patients. Another notable offering is the TearCare System, a wearable eyelid technology employed by ophthalmologists and optometrists for managing dry eye disease (DED). The company makes its products available across the United States, reaching hospitals, medical centers, and eye care professionals through its direct sales force and distribution partners. Founded in 2010, Sight Sciences' corporate operations are based in Menlo Park, California.
Discover more
You may be interested in